Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403528 | 0.91 | ACHE (0.47) | PDE4BACHECTSD | |
| SCHEMBL2404559 | 0.85 | CNR2 (0.39) | — | |
| SCHEMBL2404782 | 0.85 | PDE4B (0.47) | PDE4B | |
| SCHEMBL2404081 | 0.84 | BLM (0.49) | ACHE | |
| SCHEMBL2405482 | 0.84 | PDE4B (0.36) | PDE4BACHECTSD | |
| SCHEMBL2405230 | 0.84 | MAPK1 (0.51) | PDE4BACHE | |
| SCHEMBL2406182 | 0.84 | PDE4B (0.42) | PDE4BACHE | |
| SCHEMBL2410391 | 0.83 | PDE4B (0.46) | PDE4BACHE | |
| SCHEMBL2403865 | 0.80 | TDP1 (0.42) | — | |
| SCHEMBL2405217 | 0.80 | PDE4B (0.43) | PDE4BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | PDE4B 822/4885TAS1R3 772/4885TAS1R1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.